{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:14:24Z","timestamp":1792815264390,"version":"4.5.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["europeanneuropsychopharmacology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.euroneuro.2013.03.007","type":"journal-article","created":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T04:00:23Z","timestamp":1367380823000},"page":"713-724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"title":["Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?"],"prefix":"10.1016","volume":"25","author":[{"given":"Thomas A.","family":"Bayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2013.03.007_bib1","first-page":"146","article-title":"\u00dcber eine eigenartige Erkrankung der Hirnrinde","volume":"64","author":"Alzheimer","year":"1907","journal-title":"Allg. Z. Psychiatr. Psych. Gerichtl. Med."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib2","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.bbrc.2006.10.093","article-title":"TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"351","author":"Arai","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib3","doi-asserted-by":"crossref","first-page":"6972","DOI":"10.1523\/JNEUROSCI.23-18-06972.2003","article-title":"Reversible paired helical filament-like phosphorylation of tau is an adaptive process associated with neuronal plasticity in hibernating animals","volume":"23","author":"Arendt","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib4","doi-asserted-by":"crossref","first-page":"9115","DOI":"10.1523\/JNEUROSCI.2361-07.2007","article-title":"Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements","volume":"27","author":"Asuni","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrn2194","article-title":"Tau-mediated neurodegeneration in Alzheimer's disease and related disorders","volume":"8","author":"Ballatore","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.1853202","article-title":"Solution structures of beta peptide and its constituent fragments: relation to amyloid deposition","volume":"253","author":"Barrow","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib7","first-page":"2","article-title":"Intracellular accumulation of amyloid-beta\u2014a predictor for synaptic dysfunction and neuron loss in Alzheimer's disease","volume":"10","author":"Bayer","year":"2010","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nn.3028","article-title":"The toxic A[beta] oligomer and Alzheimer's disease: an emperor in need of clothes","volume":"29","author":"Benilova","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib9","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1172\/JCI24761","article-title":"The genetic epidemiology of neurodegenerative disease","volume":"115","author":"Bertram","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib10","first-page":"1","article-title":"Alpha-synuclein posttranslational modification and alternative splicing as a trigger for neurodegeneration","author":"Beyer","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0140-6736(06)69113-7","article-title":"Alzheimer's disease","volume":"368","author":"Blennow","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib12","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00401-010-0719-5","article-title":"Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis","volume":"120","author":"Boche","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib13","doi-asserted-by":"crossref","first-page":"16559","DOI":"10.1523\/JNEUROSCI.4363-10.2010","article-title":"Immunotherapy targeting pathological tau prevents cognitive decline in a New tangle mouse model","volume":"30","author":"Boutajangout","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00401-006-0127-z","article-title":"Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry","volume":"112","author":"Braak","year":"2006","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological staging of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib16","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00401-009-0539-7","article-title":"APP\/PS1KI bigenic mice develop early synaptic deficits and hippocampus atrophy","volume":"117","author":"Breyhan","year":"2009","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1042\/bj2730127","article-title":"Tau in Alzheimer neurofibrillary tangles. N- and C-terminal regions are differentially associated with paired helical filaments and the location of a putative abnormal phosphorylation site","volume":"273","author":"Brion","year":"1991","journal-title":"Biochem. J."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib18","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrm2873","article-title":"Prion-like transmission of protein aggregates in neurodegenerative diseases","volume":"11","author":"Brundin","year":"2010","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2353\/ajpath.2007.070182","article-title":"TDP-43 in familial and sporadic frontotemporal lobar degeneration with ubiquitin inclusions","volume":"171","author":"Cairns","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(97)02073-4","article-title":"Conformational disease","volume":"350","author":"Carrell","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib21","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/S0002-9440(10)63388-3","article-title":"Massive CA1\/2 neuronal loss with intraneuronal and N-terminal truncated A{beta}42 accumulation in a novel Alzheimer transgenic model","volume":"165","author":"Casas","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib22","doi-asserted-by":"crossref","first-page":"34457","DOI":"10.1074\/jbc.M111.229633","article-title":"Passive immunization with anti-tau antibodies in two transgenic models","volume":"286","author":"Chai","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2174\/1389450043345236","article-title":"Posttranslational modifications of tau\u2014role in human tauopathies and modeling in transgenic animals","volume":"5","author":"Chen","year":"2004","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib24","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/j.neurobiolaging.2008.07.022","article-title":"Intracellular A[beta] triggers neuron loss in the cholinergic system of the APP\/PS1KI mouse model of Alzheimer's disease","volume":"31","author":"Christensen","year":"2010","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib25","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00401-008-0451-6","article-title":"Transient intraneuronal Abeta rather than extracellular plaque pathology correlates with neuron loss in the frontal cortex of APP\/PS1KI mice","volume":"116","author":"Christensen","year":"2008","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib26","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s00401-010-0666-1","article-title":"Accumulation of intraneuronal Abeta correlates with ApoE4 genotype","volume":"119","author":"Christensen","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib27","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0166-2236(97)01213-7","article-title":"The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease","volume":"21","author":"Clayton","year":"1998","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib28","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nrmicro2650","article-title":"De novo generation of prion strains","volume":"9","author":"Colby","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib29","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.cell.2012.03.037","article-title":"Direct observation of the interconversion of normal and toxic forms of alpha-synuclein","volume":"149","author":"Cremades","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib30","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1056\/NEJMp1007051","article-title":"Traumatic Brain Injury \u2014 Football, Warfare, and Long-Term Effects","volume":"363","author":"DeKosky","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib31","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1471-4159.2011.07458.x","article-title":"Clinical trials in Alzheimer's disease': immunotherapy approaches","volume":"120","author":"Delrieu","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib32","doi-asserted-by":"crossref","first-page":"8850","DOI":"10.1073\/pnas.151261398","article-title":"Peripheral anti-Abeta antibody alters CNS and plasma Abeta clearance and decreases brain Abeta burden in a mouse model of Alzheimer's disease","volume":"98","author":"DeMattos","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib33","first-page":"1","article-title":"Neuropathology of non-Alzheimer degenerative disorders","volume":"3","author":"Dickson","year":"2009","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib34","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/nn842","article-title":"Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model","volume":"5","author":"Dodart","year":"2002","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib35","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1021\/bi0272151","article-title":"Metal binding and oxidation of amyloid-\u03b2 within isolated senile plaque cores: raman microscopic evidence","volume":"42","author":"Dong","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib36","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1091\/mbc.3.10.1141","article-title":"Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau","volume":"3","author":"Drechsel","year":"1992","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib37","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00401-009-0532-1","article-title":"Classification and basic pathology of Alzheimer disease","volume":"118","author":"Duyckaerts","year":"2009","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1750-3639.2006.tb00563.x","article-title":"Genetic alterations of the BRI2 gene: familial British and Danish dementias","volume":"16","author":"Ghiso","year":"2006","journal-title":"Brain Pathol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib39","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib40","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0006-291X(84)80190-4","article-title":"Alzheimer\u00b4s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein","volume":"120","author":"Glenner","year":"1984","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib41","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.tins.2010.04.003","article-title":"The propagation of prion-like protein inclusions in neurodegenerative diseases","volume":"33","author":"Goedert","year":"2010","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib42","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1007\/s00702-004-0221-0","article-title":"Post-translational modifications of tau protein in Alzheimer's disease","volume":"112","author":"Gong","year":"2005","journal-title":"J. Neural Transm."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib43","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00401-010-0679-9","article-title":"Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease","volume":"119","author":"Gouras","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib44","doi-asserted-by":"crossref","first-page":"9511","DOI":"10.1021\/bi00198a017","article-title":"Domains of tau protein and interactions with microtubules","volume":"33","author":"Gustke","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib45","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid [beta]-peptide","volume":"8","author":"Haass","year":"2007","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib46","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib47","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib48","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S0140-6736(08)61075-2","article-title":"Long-term effects of A\u03b242 immunization in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial","volume":"372","author":"Holmes","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib49","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/31508","article-title":"Association of missense and 5\u2032-splice-site mutations in tau with the inherited dementia FTDP-17","volume":"393","author":"Hutton","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib50","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/0006-8993(96)00014-5","article-title":"The synaptic protein NACP is abnormally expressed during the progression of Alzheimer's disease","volume":"720","author":"Iwai","year":"1996","journal-title":"Brain Res"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib51","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0896-6273(94)90458-8","article-title":"Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43)","volume":"13","author":"Iwatsubo","year":"1994","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib52","doi-asserted-by":"crossref","first-page":"38825","DOI":"10.1074\/jbc.R111.288308","article-title":"Pyroglutamate Abeta\u2014a hatchet man in Alzheimer disease","volume":"286","author":"Jawhar","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib53","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/383707a0","article-title":"Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia","volume":"383","author":"Joutel","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib54","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/325733a0","article-title":"The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor","volume":"325","author":"Kang","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib55","doi-asserted-by":"crossref","first-page":"931","DOI":"10.4161\/hv.6.11.12689","article-title":"Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease","volume":"6","author":"Kayed","year":"2010","journal-title":"Hum. Vaccines"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib56","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib57","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/nm1747","article-title":"Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease","volume":"14","author":"Kordower","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib58","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1038\/emboj.2011.138","article-title":"Extracellular phosphorylation of the amyloid [beta]-peptide promotes formation of toxic aggregates during the pathogenesis of Alzheimer's disease","volume":"30","author":"Kumar","year":"2011","journal-title":"EMBO J."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib59","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0925-4439(98)00014-3","article-title":"Irreversible dimerization\/tetramerization and post-translational modifications inhibit proteolytic degradation of A beta peptides of Alzheimer's disease","volume":"1406","author":"Kuo","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib60","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00401-007-0226-5","article-title":"TDP-43 proteinopathy: the neuropathology underlying major forms of sporadic and familial frontotemporal lobar degeneration and motor neuron disease","volume":"114","author":"Kwong","year":"2007","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib61","doi-asserted-by":"crossref","first-page":"a006437","DOI":"10.1101\/cshperspect.a006437","article-title":"Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets","volume":"1","author":"Lee","year":"2011","journal-title":"Cold Spring Harbor Perspect. Med."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib62","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nm1746","article-title":"Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation","volume":"14","author":"Li","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib63","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/ana.21147","article-title":"Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations","volume":"61","author":"Mackenzie","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib64","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.neuint.2010.12.023","article-title":"Post-translational modifications of tau protein: Implications for Alzheimer's disease","volume":"58","author":"Martin","year":"2011","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib65","first-page":"201","article-title":"Altered presynaptic protein NACP is associated with plaque formation and neurodegeneration in Alzheimer's disease","volume":"148","author":"Masliah","year":"1996","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib66","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.neuron.2005.05.010","article-title":"Effects of \u03b1-synuclein immunization in a mouse model of Parkinson's disease","volume":"46","author":"Masliah","year":"2005","journal-title":"Neuron"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib67","doi-asserted-by":"crossref","first-page":"e19338","DOI":"10.1371\/journal.pone.0019338","article-title":"Passive Immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of lewy body disease","volume":"6","author":"Masliah","year":"2011","journal-title":"PLoS ONE"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib68","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.82.12.4245","article-title":"Amyloid plaque core protein in Alzheimer disease and Down syndrome","volume":"82","author":"Masters","year":"1985","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib69","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.febslet.2009.01.037","article-title":"Inhibition of alpha-synuclein fibril assembly by small molecules: analysis using epitope-specific antibodies","volume":"583","author":"Masuda","year":"2009","journal-title":"FEBS Lett."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib70","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/nm790","article-title":"Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4\u201310 and inhibit cytotoxicity and fibrillogenesis","volume":"8","author":"McLaurin","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib71","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nature06616","article-title":"Rapid appearance and local toxicity of amyloid-beta plaques in a mouse model of Alzheimer's disease","volume":"451","author":"Meyer-Luehmann","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib72","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1038\/nn1022","article-title":"Extracellular amyloid formation and associated pathology in neural grafts","volume":"6","author":"Meyer-Luehmann","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib73","doi-asserted-by":"crossref","first-page":"3839","DOI":"10.1097\/00001756-200112040-00047","article-title":"Phosphorylation of amyloid-[beta] at the serine 26 residue by human cdc2 kinase","volume":"12","author":"Milton","year":"2001","journal-title":"NeuroReport"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib74","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1365-2796.2010.02315.x","article-title":"Immunotherapy for Alzheimer's disease.","volume":"269","author":"Morgan","year":"2011","journal-title":"J. Int. Med."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib75","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1038\/35050116","article-title":"A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease","volume":"408","author":"Morgan","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib76","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1620\/tjem.174.251","article-title":"Racemization: its biological significance on neuropathogenesis of Alzheimer's disease","volume":"174","author":"Mori","year":"1994","journal-title":"Tohoku J. Exp. Med."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib77","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/nrd3370","article-title":"2010 FDA drug approvals","volume":"10","author":"Mullard","year":"2011","journal-title":"Nat. Rev. Drug. Discovery"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib78","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/01.jnen.0000248554.45456.58","article-title":"TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions","volume":"66","author":"Neumann","year":"2007","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib79","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1126\/science.1134108","article-title":"Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis","volume":"314","author":"Neumann","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib80","doi-asserted-by":"crossref","first-page":"10129","DOI":"10.1523\/JNEUROSCI.1202-06.2006","article-title":"Intraneuronal beta-Amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation","volume":"26","author":"Oakley","year":"2006","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib81","series-title":"Progress in Brain Research","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0079-6123(10)83007-9","article-title":"Role of post-translational modifications in modulating the structure, function and toxicity of \u03b1-synuclein: Implications for Parkinson's disease pathogenesis and therapies","author":"Oueslati","year":"2010"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib82","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: the pharmaceutical industry's grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug. Discovery"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib83","doi-asserted-by":"crossref","first-page":"23895","DOI":"10.1074\/jbc.270.41.23895","article-title":"Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro","volume":"270","author":"Pike","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib84","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1056\/NEJM199511093331902","article-title":"Apolipoprotein E, dementia, and cortical deposition of \u03b2-amyloid protein","volume":"333","author":"Polvikoski","year":"1995","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib85","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","article-title":"Mutation in the alpha-synuclein gene identified in families with Parkinson's disease","volume":"276","author":"Polymeropoulos","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib86","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00401-010-0690-1","article-title":"Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease","volume":"120","author":"Portelius","year":"2010","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib87","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000113700","article-title":"Progress in the active immunotherapeutic approach to alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis","volume":"5","author":"Pride","year":"2008","journal-title":"Neurodeg. Dis."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib88","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1126\/science.1675487","article-title":"Molecular biology of prion disease","volume":"252","author":"Prusiner","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib89","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/332323a0","article-title":"Reshaping human antibodies for therapy","volume":"332","author":"Riechmann","year":"1988","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib90","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1016\/S0021-9258(18)53661-9","article-title":"Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease","volume":"268","author":"Roher","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib91","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib92","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/14712598.2011.578573","article-title":"Solanezumab for Alzheimer's disease","volume":"11","author":"Samadi","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib93","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib94","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000090365","article-title":"A\u03b2 Immunotherapy: lessons learned for potential treatment of Alzheimer's disease","volume":"2","author":"Schenk","year":"2005","journal-title":"Neurodeg. Dis"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib95","doi-asserted-by":"crossref","first-page":"7072","DOI":"10.1021\/bi900818a","article-title":"Pyroglutamate Formation Influences Solubility and Amyloidogenicity of Amyloid Peptides","volume":"48","author":"Schlenzig","year":"2009","journal-title":"Biochemistry"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib96","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/j.1471-4159.2012.07707.x","article-title":"N-terminal Pyroglutamate (pGlu) formation of A\u03b238 and A\u03b240 Enforces Oligomer Formation and Potency to Disrupt Hippocampal LTP","volume":"121","author":"Schlenzig","year":"2012","journal-title":"J. Neurochem."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib97","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/nm.2460","article-title":"Resolving controversies on the path to Alzheimer's therapeutics","volume":"17","author":"Selkoe","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib98","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1248\/bpb.28.1590","article-title":"Biological significance of isoaspartate and its repair system","volume":"28","author":"Shimizu","year":"2005","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib99","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1006\/jsbi.2000.4221","article-title":"Review: history of the amyloid fibril","volume":"130","author":"Sipe","year":"2000","journal-title":"J. Struct. Biol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib100","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/42166","article-title":"Alpha-synuclein in Lewy bodies","volume":"388","author":"Spillantini","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib101","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/hmg\/ddp468","article-title":"Mutations in NOTCH3 cause the formation and retention of aggregates in the endoplasmic reticulum, leading to impaired cell proliferation","volume":"19","author":"Takahashi","year":"2010","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib102","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1126\/science.2949367","article-title":"The amyloid protein gene: cDNA cloning, mRNA distribution, and genetic linkage near the Alzheimer locus","volume":"235","author":"Tanzi","year":"1987","journal-title":"Science"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib103","doi-asserted-by":"crossref","first-page":"10205","DOI":"10.1016\/S0021-9258(17)34045-0","article-title":"Racemization of Asp23 residue affects the aggregation properties of Alzheimer amyloid beta protein analogues","volume":"269","author":"Tomiyama","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib104","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1161\/01.STR.22.10.1297","article-title":"Autosomal dominant syndrome with strokelike episodes and leukoencephalopathy","volume":"22","author":"Tournier-Lasserve","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib105","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/WNF.0b013e31823a13d3","article-title":"Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid \u03b2 monoclonal antibody solanezumab in Japanese and White Patients with mild to moderate alzheimer disease","volume":"35","author":"Uenaka","year":"2012","journal-title":"Clin. Neuropharm."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib106","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1073\/pnas.0606201104","article-title":"Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis","volume":"104","author":"Urushitani","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib107","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1749-6632.2000.tb06377.x","article-title":"CADASIL: hereditary arteriopathy leading to multiple brain infarcts and dementia","volume":"903","author":"Viitanen","year":"2000","journal-title":"Ann. NY Acad. Sci."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib108","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s12035-012-8296-3","article-title":"The \u201cJanus-Faced Role\u201d of autophagy in neuronal sickness: focus on neurodegeneration","volume":"46","author":"Viscomi","year":"2012","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib109","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0197-4580(00)00160-3","article-title":"The cerebral proteopathies","volume":"21","author":"Walker","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.euroneuro.2013.03.007_bib110","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.molmed.2008.09.001","article-title":"TDP-43: an emerging new player in neurodegenerative diseases","volume":"14","author":"Wang","year":"2008","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib111","doi-asserted-by":"crossref","first-page":"3745","DOI":"10.1523\/JNEUROSCI.23-09-03745.2003","article-title":"Intracranially administered anti-\u03b1\u03b2 antibodies reduce \u03b2-amyloid deposition by mechanisms both independent of and associated with microglial activation","volume":"23","author":"Wilcock","year":"2003","journal-title":"J. Neurosci."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib112","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","article-title":"Safety, tolerability, and antibody response of active A\u03b2 immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study","volume":"11","author":"Winblad","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib113","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00401-009-0557-5","article-title":"Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model","volume":"118","author":"Wirths","year":"2009","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib114","doi-asserted-by":"crossref","first-page":"41517","DOI":"10.1074\/jbc.M110.178707","article-title":"Identification of low molecular weight pyroglutamate Abeta oligomers in Alzheimer disease: a novel tool for therapy and diagnosis","volume":"285","author":"Wirths","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib115","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1471-4159.2004.02737.x","article-title":"A modified beta-amyloid hypothesis: intraneuronal accumulation of the beta-amyloid peptide\u2014the first step of a fatal cascade","volume":"91","author":"Wirths","year":"2004","journal-title":"J. Neurochem."},{"key":"10.1016\/j.euroneuro.2013.03.007_bib116","doi-asserted-by":"crossref","first-page":"8154","DOI":"10.1074\/jbc.M111.308601","article-title":"Pyroglutamate amyloid \u03b2 (A\u03b2) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease","volume":"287","author":"Wittnam","year":"2012","journal-title":"J. Biol. Chem."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13001107?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X13001107?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T17:17:54Z","timestamp":1644945474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X13001107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":116,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0924977X13001107"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.03.007","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proteinopathies, a core concept for understanding and ultimately treating degenerative disorders?","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2013.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}